ロード中...
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
BACKGROUND: Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma and non-small cell lung cancer (NSCLC). Despite important clinical benefit...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4791920/ https://ncbi.nlm.nih.gov/pubmed/26981243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0117-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|